Friday, 16 October 2026European Markets

ELMERA GROUP And MAGNORA Have A High Dividend Yield And Return On Equity In The Utilities Sector.

Loading stream...

(VIANEWS) - ELMERA GROUP (ELMRA.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Utilities sector.

Financial Asset Price Forward Dividend Yield Return on Equity
ELMERA GROUP (ELMRA.OL) kr24.70 6.79% 5.02%
MAGNORA (MGN.OL) kr31.75 1.18% 52.28%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ELMERA GROUP (ELMRA.OL)

6.79% Forward Dividend Yield and 5.02% Return On Equity

Elmera Group ASA, together with its subsidiaries, engages in the purchase, sale, and portfolio management of electrical power to households, private and public companies, and municipalities in Norway. It operates through Consumer, Business, and Nordic segments. The Consumer segment sells electrical power and related services to private consumers. The Business segment sells electrical power and related services to business consumers. The Nordic segment sells electrical power and related services to consumers in Finland and Sweden. The company also manages, researches, and develops products and services related to electrical power; and offers payment solutions. In addition, it provides mobile phone services to private customers. The company was formerly known as Fjordkraft Holding ASA and changed its name to Elmera Group ASA in April 2022. Elmera Group ASA was founded in 2001 and is headquartered in Bergen, Norway.

Earnings Per Share

As for profitability, ELMERA GROUP has a trailing twelve months EPS of kr0.56.

PE Ratio

ELMERA GROUP has a trailing twelve months price to earnings ratio of 44.11. Meaning, the purchaser of the share is investing kr44.11 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.02%.

Growth Estimates Quarters

The company's growth estimates for the current quarter is a negative 70.9% and positive 500% for the next.

More news about ELMERA GROUP.

2. MAGNORA (MGN.OL)

1.18% Forward Dividend Yield and 52.28% Return On Equity

Magnora ASA operates as a renewable energy development company. It primarily focuses on developing wind and solar photovoltaic (PV) projects. The company also hold license agreements with the Dana Western Isles and Shell Penguins FPSO. It serves oil companies and marine contractors in the United Kingdom, Norway, and Sweden. The company was formerly known as Sevan Marine ASA and changed its name to Magnora ASA in October 2018. Magnora ASA was incorporated in 2001 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, MAGNORA has a trailing twelve months EPS of kr4.01.

PE Ratio

MAGNORA has a trailing twelve months price to earnings ratio of 7.92. Meaning, the purchaser of the share is investing kr7.92 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 52.28%.

Sales Growth

MAGNORA's sales growth for the next quarter is negative 69.1%.

More news about MAGNORA.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com